Alexandra Rousseau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandra Rousseau has a total of 280 co-authors. Here are the top co-authors by number of shared publications:
- Tabassome Simon
Sorbonne Université, Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Department of Pharmacology, 27 rue Chaligny, 75012, Paris, France
9 shared publications - Francis Berenbaum
Rheumatology, Sorbonne University, INSERM CRSA, AP-HP Saint-Antoine Hospital Paris, France
7 shared publications - Jérémie Sellam
Sorbonne Université, APHP, Department of Rheumatology, Hôpital Saint-Antoine, Paris, France
6 shared publications - Emmanuel Maheu
Sorbonne Université, APHP, Department of Rheumatology, Hôpital Saint-Antoine, Paris, France
4 shared publications Sophie Tuffet
Sorbonne University, URCEST, CRB, CRC, Saint-Antoine Hospital, AP-HP, Paris, France
4 shared publications- Laurence Berard
Assistance Publique-Hôpitaux de Paris (APHP), Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST- CRB CRC), Saint-Antoine Hospital , Paris
3 shared publications
Latest Publications
- Open Access
- 17 May 2026
- Published by BMJ in BMJ Medicine
- Vol. 5 (1) , e002602
Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS)
Objective: To assess whether procalcitonin-guided decision making can safely reduce the duration of antibiotic treatment in neonatal late onset sepsis. Design: Prospective multicentre, randomised open label trial. Setting: 33 level 3 and level 2B neonatology departments in France. Participants: Newborn babies born after 24 weeks’ gestation, of postconceptional age 24-45 weeks and after 4 days of life, weighing more than 700 g, with suspected or proven late onset sepsis, requiring antibiotics for more than 48 hours, and without meningitis, septic shock, and deep-seated infection. Interventions: Participants were randomly assigned to procalcitonin-guided or usual care antibiotic treatment. In the procalcitonin-guided group, procalcitonin concentration was measured at randomisation and then every two days. A non-binding recommendation to discontinue antibiotics was given if the procalcitonin concentration was 0.5 µg/L or lower. In the usual care group, treatment was provided according to local protocols. Main outcome measures: The primary outcome was the duration of antibiotic treatment (under the superiority hypothesis). The key secondary outcome was non-inferiority for mortality (margin 3%) at day 28 after randomisation. Results: Between February 2019 and February 2023, 248 newborns were randomised to the procalcitonin-guided group and 256 to the usual care group. In the intention-to-treat analysis, the median duration of antibiotic treatment was eight days (interquartile range (IQR) 5.0-12.0) in the procalcitonin-guided group versus 10 days (8.0-13.0) in the usual care group (absolute difference between groups −2.0 (IQR −3.8 to −1.0), P<0.001). At day 28, the proportion of death was six of 248 newborns (2.4%) in the procalcitonin-guided group versus 10 of 256 (3.9%) in the usual care group (absolute difference between groups −1.5% (95% confidence interval (CI) −5.0 to 1.8). The proportion of recurrence was seven of 248 (2.8%) newborns in the procalcitonin-guided group versus 10 (3.9%) of 256 in the usual care group (absolute difference between groups −1.1% (95% CI −4.6 to 2.3). Conclusion: In this study population, the use of procalcitonin significantly reduced the duration of antibiotic treatment in neonatal late onset sepsis, without increasing mortality or serious adverse events. Trial registration: NCT03730636 .
- 17 May 2026
- Published by BMJ in BMJ Medicine
- Vol. 5 (1) , e002602
Open AccessProcalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS)
Objective: To assess whether procalcitonin-guided decision making can safely reduce the duration of antibiotic treatment in neonatal late onset sepsis. Design: Prospective multicentre, randomised open label trial. Setting: 33 level 3 and level 2B neonatology departments in France. Participants: Newborn babies born after 24 weeks’ gestation, of postconceptional age 24-45 weeks and after 4 days of life, weighing more than 700 g, with suspected or proven late onset sepsis, requiring antibiotics for more than 48 hours, and without meningitis, septic shock, and deep-seated infection. Interventions: Participants were randomly assigned to procalcitonin-guided or usual care antibiotic treatment. In the procalcitonin-guided group, procalcitonin concentration was measured at randomisation and then every two days. A non-binding recommendation to discontinue antibiotics was given if the procalcitonin concentration was 0.5 µg/L or lower. In the usual care group, treatment was provided according to local protocols. Main outcome measures: The primary outcome was the duration of antibiotic treatment (under the superiority hypothesis). The key secondary outcome was non-inferiority for mortality (margin 3%) at day 28 after randomisation. Results: Between February 2019 and February 2023, 248 newborns were randomised to the procalcitonin-guided group and 256 to the usual care group. In the intention-to-treat analysis, the median duration of antibiotic treatment was eight days (interquartile range (IQR) 5.0-12.0) in the procalcitonin-guided group versus 10 days (8.0-13.0) in the usual care group (absolute difference between groups −2.0 (IQR −3.8 to −1.0), P<0.001). At day 28, the proportion of death was six of 248 newborns (2.4%) in the procalcitonin-guided group versus 10 of 256 (3.9%) in the usual care group (absolute difference between groups −1.5% (95% confidence interval (CI) −5.0 to 1.8). The proportion of recurrence was seven of 248 (2.8%) newborns in the procalcitonin-guided group versus 10 (3.9%) of 256 in the usual care group (absolute difference between groups −1.1% (95% CI −4.6 to 2.3). Conclusion: In this study population, the use of procalcitonin significantly reduced the duration of antibiotic treatment in neonatal late onset sepsis, without increasing mortality or serious adverse events. Trial registration: NCT03730636 .
- Open Access
- 13 April 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (5)
Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis
- 13 April 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (5)
Open AccessFracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis
- 14 July 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1259-1270
PBC-HOPE: A Randomized Controlled Trial of Hypnosis and Psychoeducation in Women With Primary Biliary Cholangitis and Fatigue
INTRODUCTION: Fatigue is the main symptom of primary biliary cholangitis (PBC) but has not yet been improved by any therapeutic intervention. This study evaluated the efficacy and safety of hypnosis and psychoeducation in improving fatigue associated with PBC (PBC-HOPE ClinicalTrial.gov number, NCT03630718). METHODS: Fifty-five women with PBC and significant fatigue, defined by a PBC-40 fatigue score ≥ 33, were randomly assigned to standard care (SC) alone (n = 18), SC plus hypnosis (n = 18), and SC plus psychoeducation (n = 19), with 4 weekly sessions for the intervention groups. Self-report questionnaires, including the PBC-40, were completed at inclusion (D0) and week 12. The first 8 patients in each group were interviewed at both times. The primary outcome was the difference in PBC-40 fatigue score between D0 and week 12. The secondary and exploratory outcomes were the psychometric scores and interview findings. RESULTS: The primary outcome was not achieved, with a median (interquartile range) difference in PBC-40 fatigue score of −3.0 (−10.0 to 1.0), −6.0 (−8.0 to −4.0), and −6.0 (−11.5 to −4.8) for SC, SC-hypnosis, and SC-psychoeducation, respectively. The quantitative secondary outcomes were consistent with this result. The qualitative exploratory outcomes indicated that both interventions positively modified patients' perceptions of fatigue, underlining the appropriation of the intervention. No serious adverse events occurred. DISCUSSION: At 12 weeks, hypnosis and psychoeducation interventions were not associated with a significant reduction in quantitative measures of fatigue associated with PBC. However, the qualitative changes in perceived fatigue associated with these interventions suggest that maintenance sessions could be beneficial in the longer term.
- 14 July 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1259-1270
PBC-HOPE: A Randomized Controlled Trial of Hypnosis and Psychoeducation in Women With Primary Biliary Cholangitis and Fatigue
INTRODUCTION: Fatigue is the main symptom of primary biliary cholangitis (PBC) but has not yet been improved by any therapeutic intervention. This study evaluated the efficacy and safety of hypnosis and psychoeducation in improving fatigue associated with PBC (PBC-HOPE ClinicalTrial.gov number, NCT03630718). METHODS: Fifty-five women with PBC and significant fatigue, defined by a PBC-40 fatigue score ≥ 33, were randomly assigned to standard care (SC) alone (n = 18), SC plus hypnosis (n = 18), and SC plus psychoeducation (n = 19), with 4 weekly sessions for the intervention groups. Self-report questionnaires, including the PBC-40, were completed at inclusion (D0) and week 12. The first 8 patients in each group were interviewed at both times. The primary outcome was the difference in PBC-40 fatigue score between D0 and week 12. The secondary and exploratory outcomes were the psychometric scores and interview findings. RESULTS: The primary outcome was not achieved, with a median (interquartile range) difference in PBC-40 fatigue score of −3.0 (−10.0 to 1.0), −6.0 (−8.0 to −4.0), and −6.0 (−11.5 to −4.8) for SC, SC-hypnosis, and SC-psychoeducation, respectively. The quantitative secondary outcomes were consistent with this result. The qualitative exploratory outcomes indicated that both interventions positively modified patients' perceptions of fatigue, underlining the appropriation of the intervention. No serious adverse events occurred. DISCUSSION: At 12 weeks, hypnosis and psychoeducation interventions were not associated with a significant reduction in quantitative measures of fatigue associated with PBC. However, the qualitative changes in perceived fatigue associated with these interventions suggest that maintenance sessions could be beneficial in the longer term.
- Open Access
- 5 June 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (3) , 100639
Association between weather features and symptoms in hand osteoarthritis: Results from the DIGICOD cohort
- 5 June 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (3) , 100639
Open AccessAssociation between weather features and symptoms in hand osteoarthritis: Results from the DIGICOD cohort
- Open Access
- 20 May 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (3) , 100626
Greater pain and functional impairment in chronic erosive hand osteoarthritis compared to treated rheumatoid arthritis: A comparative study
- 20 May 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 7 (3) , 100626
Open AccessGreater pain and functional impairment in chronic erosive hand osteoarthritis compared to treated rheumatoid arthritis: A comparative study
- Open Access
- 18 January 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-7
Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants
Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech). Methods First booster of the vaccines was administered in adult participants previously primed with 2 doses of MV ancestral strain BNT162b2. A subset of these participants with available blood samples collected at Day 0 (D0), at 28 days (D28), and 3 months (M3) post-booster were contacted for additional testing (195/208 participants). The persistence of cross-neutralizing antibodies, including against Omicron BA.1 and BA.4/5, up to 3 months after boosting was evaluated using a validated pseudovirus neutralization assay. Results Across the whole population, MVB.1.351 vaccine induces highest NAbs titers against Omicron BA.1 and BA.4/5 variants at D28 and M3 post-booster. In participants with SARS-CoV-2 infection between D28 and M3, both MVB.1.351 and BNT162b2 vaccine groups show an increase in GMTs against Omicron BA.1 and Omicron BA.4/5 following infection. Among uninfected participants, the ratio of M3 to D28 GMTs was higher for the MVB.1.351 group than the BNT162b2 group against Omicron BA.1 (0.64 [0.53;0.77] versus 0.43 [0.35;0.53]), Omicron BA.4/5 (0.61 [0.50; 0.75] versus 0.44 [0.34; 0.56]), and D614 (0.68 [0.58,0.81] versus 0.46 [0.39,0.55]). Conclusions The MVB.1.351 vaccine induces higher and durable cross-neutralizing antibodies against Omicron subvariants up to 3 months after boosting compared to an MV ancestral and mRNA BNT162b2 booster vaccine.
- 18 January 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-7
Open AccessBeta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants
Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech). Methods First booster of the vaccines was administered in adult participants previously primed with 2 doses of MV ancestral strain BNT162b2. A subset of these participants with available blood samples collected at Day 0 (D0), at 28 days (D28), and 3 months (M3) post-booster were contacted for additional testing (195/208 participants). The persistence of cross-neutralizing antibodies, including against Omicron BA.1 and BA.4/5, up to 3 months after boosting was evaluated using a validated pseudovirus neutralization assay. Results Across the whole population, MVB.1.351 vaccine induces highest NAbs titers against Omicron BA.1 and BA.4/5 variants at D28 and M3 post-booster. In participants with SARS-CoV-2 infection between D28 and M3, both MVB.1.351 and BNT162b2 vaccine groups show an increase in GMTs against Omicron BA.1 and Omicron BA.4/5 following infection. Among uninfected participants, the ratio of M3 to D28 GMTs was higher for the MVB.1.351 group than the BNT162b2 group against Omicron BA.1 (0.64 [0.53;0.77] versus 0.43 [0.35;0.53]), Omicron BA.4/5 (0.61 [0.50; 0.75] versus 0.44 [0.34; 0.56]), and D614 (0.68 [0.58,0.81] versus 0.46 [0.39,0.55]). Conclusions The MVB.1.351 vaccine induces higher and durable cross-neutralizing antibodies against Omicron subvariants up to 3 months after boosting compared to an MV ancestral and mRNA BNT162b2 booster vaccine.
- Open Access
- 30 May 2023
- Published by BMJ in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 1039.2-1040
POS1373 EROSIVE OR INFLAMMATORY HAND OA (HOA): A MORE SEVERE DISEASE? CROSS-SECTIONAL STUDY OF BASELINE ASSOCIATED RISK FACTORS IN PATIENTS FROM THE DIGICOD COHORT
Background Erosive HOA (EHOA), defined by an erosive radiographic joint and inflammatory HOA (IHOA) defined by the presence of clinical synovitis are frequent in HOA. The association with specific risk factors and a more severe disease, remains still debated. Objectives To identify demographic, disease-related and clinical factors as risk factors for EHOA or IHAO. Methods Clinical and radiographic data were extracted from baseline data of the 6-years prospective longitudinal HOA French cohort DIGICOD [1]. Demographic and hand OA clinical and radiological data were compared at baseline between EHOA (≥1 erosive joint in E- or R-phase according to Verbruggen scoring) versus non EHOA, and IHOA (≥ 1 joint with clinical synovitis) vs non IHOA groups. A model of logistic regression analysis was performed for each demographic and clinical HOA-related studied parameter to identify factors associated with EHOA and/or IHOA. Analyses were adjusted for age, sex and body mass index. Results are expressed as Odd Ratios and their 95%Confidence Interval (OR (95%CI)). Results 425 patients were analyzed, 195 EHOA (46%), 185 IHOA (43%), with 113 both EHOA and IHOA (27%). The risk of EHOA was reduced by a half in case of current/past professional occupation involving hands (OR 0.6; 95%CI: 0,4; 0.9) and by at least 0.6 (0.3;1.0) if grip strength ≥ 19kg. It was increased by at least 2.0 (1.1; 3.5) if OA duration was ≥6 years, by 2.6 (1.7; 3.9) if aesthetic damage scored ≥40 on a 0-100 mm VAS, by 2.2 (1.4; 3.5) if ≥2 painful joints on pressure, by 2 (1.3; 3,1) if the AUSCAN stiffness subscale scored ≥20 (0-100 VAS), by 2.3 (1,5; 3,5) if the Functional Index for HOA (FIHOA) scored ≥20 (score normalized to 0-100). The risk of IHOA was increased by 2.4 (1.4; 4.0) if OA duration was ≥11 years versus < 6 years, by 1.8 (1.1; 3.0) if pain at rest VAS was ≥40 and by 2.1 (1.4; 3.2) if pain on activity was ≥40, by 2.5 (1.6; 3.8) if aesthetic damage scored ≥40, by 2.5 (1.5; 4.1) if ≥2 painful joints on pressure and by 1.9 (1.2; 2.9) if ≥2 spontaneous painful joints, by 1.9 (1.2; 3.0) if AUSCAN stiffness subscale ≥40, by 1.8 (1.2; 2.7) if the FIHOA was ≥20. Structural damage was higher in both EHOA and IHOA than in those without EHOA and IHOA, respectively: the mean ±standard deviation number of joints at a Kellgren-Lawrence grade ≥2 was 18±5 in erosive vs 13±6 in non-erosive patients and 18±6 vs 13±6 in IHOA vs non IHOA. Conclusion There was a high prevalence of EHOA and IHOA in our cohort, partly due to a tertiary-care recruitment. Structural damage was more severe in both phenotypes than in those without erosive or inflammatory signs. There was an inverse correlation between hand use and EHOA, confirming that EHOA is rather linked to systemic factors. Risk factors for both EHOA and IHOA were a longer disease duration, a higher aesthetic damage (notably in IHOA), number of painful joints on pressure, stiffness, and functional impairment (FIHOA). IHOA was also associated with more pain. Prospective longitudinal studies are needed to confirm these risk factors. Reference [1]Sellam J, Maheu E, Crema MD, et al. Joint Bone Spine. 2021;88:105171. Acknowledgements: NIL. Disclosure of Interests None Declared.
- 30 May 2023
- Published by BMJ in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 1039.2-1040
Open AccessPOS1373 EROSIVE OR INFLAMMATORY HAND OA (HOA): A MORE SEVERE DISEASE? CROSS-SECTIONAL STUDY OF BASELINE ASSOCIATED RISK FACTORS IN PATIENTS FROM THE DIGICOD COHORT
Background Erosive HOA (EHOA), defined by an erosive radiographic joint and inflammatory HOA (IHOA) defined by the presence of clinical synovitis are frequent in HOA. The association with specific risk factors and a more severe disease, remains still debated. Objectives To identify demographic, disease-related and clinical factors as risk factors for EHOA or IHAO. Methods Clinical and radiographic data were extracted from baseline data of the 6-years prospective longitudinal HOA French cohort DIGICOD [1]. Demographic and hand OA clinical and radiological data were compared at baseline between EHOA (≥1 erosive joint in E- or R-phase according to Verbruggen scoring) versus non EHOA, and IHOA (≥ 1 joint with clinical synovitis) vs non IHOA groups. A model of logistic regression analysis was performed for each demographic and clinical HOA-related studied parameter to identify factors associated with EHOA and/or IHOA. Analyses were adjusted for age, sex and body mass index. Results are expressed as Odd Ratios and their 95%Confidence Interval (OR (95%CI)). Results 425 patients were analyzed, 195 EHOA (46%), 185 IHOA (43%), with 113 both EHOA and IHOA (27%). The risk of EHOA was reduced by a half in case of current/past professional occupation involving hands (OR 0.6; 95%CI: 0,4; 0.9) and by at least 0.6 (0.3;1.0) if grip strength ≥ 19kg. It was increased by at least 2.0 (1.1; 3.5) if OA duration was ≥6 years, by 2.6 (1.7; 3.9) if aesthetic damage scored ≥40 on a 0-100 mm VAS, by 2.2 (1.4; 3.5) if ≥2 painful joints on pressure, by 2 (1.3; 3,1) if the AUSCAN stiffness subscale scored ≥20 (0-100 VAS), by 2.3 (1,5; 3,5) if the Functional Index for HOA (FIHOA) scored ≥20 (score normalized to 0-100). The risk of IHOA was increased by 2.4 (1.4; 4.0) if OA duration was ≥11 years versus < 6 years, by 1.8 (1.1; 3.0) if pain at rest VAS was ≥40 and by 2.1 (1.4; 3.2) if pain on activity was ≥40, by 2.5 (1.6; 3.8) if aesthetic damage scored ≥40, by 2.5 (1.5; 4.1) if ≥2 painful joints on pressure and by 1.9 (1.2; 2.9) if ≥2 spontaneous painful joints, by 1.9 (1.2; 3.0) if AUSCAN stiffness subscale ≥40, by 1.8 (1.2; 2.7) if the FIHOA was ≥20. Structural damage was higher in both EHOA and IHOA than in those without EHOA and IHOA, respectively: the mean ±standard deviation number of joints at a Kellgren-Lawrence grade ≥2 was 18±5 in erosive vs 13±6 in non-erosive patients and 18±6 vs 13±6 in IHOA vs non IHOA. Conclusion There was a high prevalence of EHOA and IHOA in our cohort, partly due to a tertiary-care recruitment. Structural damage was more severe in both phenotypes than in those without erosive or inflammatory signs. There was an inverse correlation between hand use and EHOA, confirming that EHOA is rather linked to systemic factors. Risk factors for both EHOA and IHOA were a longer disease duration, a higher aesthetic damage (notably in IHOA), number of painful joints on pressure, stiffness, and functional impairment (FIHOA). IHOA was also associated with more pain. Prospective longitudinal studies are needed to confirm these risk factors. Reference [1]Sellam J, Maheu E, Crema MD, et al. Joint Bone Spine. 2021;88:105171. Acknowledgements: NIL. Disclosure of Interests None Declared.
- 15 March 2023
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 31 (7) , 976-984
Serum carboxymethyllysine concentration is associated with erosive hand osteoarthritis
- 15 March 2023
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 31 (7) , 976-984
Serum carboxymethyllysine concentration is associated with erosive hand osteoarthritis
- Open Access
- 23 December 2022
- Published by Elsevier in Journal of Tissue Viability
- Vol. 32 (1) , 20-25
Feasibility of a repositioning schedule on pressure ulcer prevention in a French Intensive Care Unit: A pre and post-intervention pilot study
- 23 December 2022
- Published by Elsevier in Journal of Tissue Viability
- Vol. 32 (1) , 20-25
Open AccessFeasibility of a repositioning schedule on pressure ulcer prevention in a French Intensive Care Unit: A pre and post-intervention pilot study
- 28 June 2022
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81, 1611-4
AB0967 IMPACT OF CARPAL TUNNEL SYNDROME ON SYMPTOMS AND STRUCTURAL SEVERITY OF HAND OSTEOARTHRITIS: RESULTS FROM THE DIGICOD COHORT.
- 28 June 2022
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81, 1611-4
AB0967 IMPACT OF CARPAL TUNNEL SYNDROME ON SYMPTOMS AND STRUCTURAL SEVERITY OF HAND OSTEOARTHRITIS: RESULTS FROM THE DIGICOD COHORT.